Pfizer, Johnson & Johnson settle high-profile Remicade biosim lawsuit on undisclosed terms

For nearly four years, pharmaceutical heavyweights Johnson & Johnson and Pfizer have sparred in court over competitive dynamics of the biosimilar industry, demanding the attention of the industry in a groundbreaking case that had some promise to serve as a bellwether for the future.